Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease
出版年份 2020 全文链接
标题
Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease
作者
关键词
-
出版物
Frontiers in Cell and Developmental Biology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-06-03
DOI
10.3389/fcell.2020.00425
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
- (2019) Jonathan L. Kaufman et al. Blood Cancer Journal
- Enantioselective synthesis and biological investigation of tetrahydro‐β‐carboline‐based HDAC6 inhibitors with improved solubility
- (2019) Elisabeth Grünstein et al. ARCHIV DER PHARMAZIE
- Posttranslational modifications and proteinopathies: how guardians of the proteome are defeated
- (2019) Heidi Olzscha BIOLOGICAL CHEMISTRY
- Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC).
- (2019) Sukeshi Patel Arora et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib for relapsed and refractory multiple myeloma
- (2019) K. Groen et al. Cancer Management and Research
- MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells
- (2019) Fang-I Huang et al. Frontiers in Oncology
- HSP90 Molecular Chaperones, Metabolic Rewiring, and Epigenetics: Impact on Tumor Progression and Perspective for Anticancer Therapy
- (2019) Valentina Condelli et al. Cells
- Epigenetic Alterations of Heat Shock Proteins (HSPs) in Cancer
- (2019) Hyun Seung Ban et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Biomarker definitions and their applications
- (2018) Robert M Califf EXPERIMENTAL BIOLOGY AND MEDICINE
- Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors
- (2018) Andreas Sellmer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Systematic analysis of protein turnover in primary cells
- (2018) Toby Mathieson et al. Nature Communications
- Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
- (2018) Amit Singh et al. Nutrients
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
- (2018) Maria Cosenza et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Histone deacetylase 6 in cancer
- (2018) Ting Li et al. Journal of Hematology & Oncology
- Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer
- (2018) Seung Yeob Hyun et al. Scientific Reports
- Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy
- (2018) Barbara Wegiel et al. Frontiers in Oncology
- The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death
- (2018) Maciej Kaliszczak et al. BRITISH JOURNAL OF CANCER
- A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer
- (2018) Toby A. Eyre et al. CANCER
- Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53
- (2018) Maria Mrakovcic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Autophagy: An Essential Degradation Program for Cellular Homeostasis and Life
- (2018) Yoomi Chun et al. Cells
- The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
- (2017) Tania Díaz et al. HAEMATOLOGICA
- Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53
- (2017) Maria Mrakovcic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Regulation of the Tumor-Suppressor BECLIN 1 by Distinct Ubiquitination Cascades
- (2017) Fahd Boutouja et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
- (2017) S K Kumar et al. LEUKEMIA
- Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment
- (2017) Vahid Salimi et al. Lipids in Health and Disease
- The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology
- (2017) Daniel N Cagney et al. NEURO-ONCOLOGY
- Protein Posttranslational Modifications: Roles in Aging and Age-Related Disease
- (2017) Ana L. Santos et al. Oxidative Medicine and Cellular Longevity
- Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function
- (2017) Naoe T. Nihira et al. Science Signaling
- HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness
- (2017) Janina Leyk et al. Cell Death & Disease
- Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines
- (2017) Xin Jin et al. Oncology Letters
- The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
- (2017) Laurence Booth et al. Oncotarget
- Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update
- (2017) Pere Llinàs-Arias et al. Open Biology
- Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine
- (2017) Krysta Mila Coyle et al. Biomed Research International
- The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
- (2017) Tania Díaz et al. HAEMATOLOGICA
- The Glycolytic Switch in Tumors: How Many Players Are Involved?
- (2017) Li Yu et al. Journal of Cancer
- Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function
- (2017) Naoe T. Nihira et al. Science Signaling
- PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.
- (2017) J. F. San-Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells
- (2016) Katrin Noack et al. ARCHIVES OF TOXICOLOGY
- Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112
- (2016) Beth E. Zucconi et al. BIOCHEMISTRY
- The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR
- (2016) L. Zhou et al. BLOOD
- Proteostasis impairment in ALS
- (2016) Céline Ruegsegger et al. BRAIN RESEARCH
- The Emerging Hallmarks of Cancer Metabolism
- (2016) Natalya N. Pavlova et al. Cell Metabolism
- Progress in the Development of non-BET Bromodomain Chemical Probes
- (2016) Natalie H. Theodoulou et al. ChemMedChem
- Bromodomain inhibitors and cancer therapy: From structures to applications
- (2016) Montserrat Pérez-Salvia et al. Epigenetics
- Trichostatin A, a histone deacetylase inhibitor suppresses NADPH Oxidase 4-Derived Redox Signalling and Angiogenesis
- (2016) Nora Y. Hakami et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer
- (2016) Mark L. McCleland et al. JOURNAL OF CLINICAL INVESTIGATION
- Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model
- (2016) Hui-Wen Chiu et al. Molecular Cancer
- Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer
- (2016) Sukeshi Patel et al. Oncotarget
- Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of α-tubulin acetylation and FGF-21 up-regulation
- (2016) Zhifei Wang et al. Scientific Reports
- Epigenetic polypharmacology: from combination therapy to multitargeted drugs
- (2016) Angel R. de Lera et al. Clinical Epigenetics
- Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
- (2016) Andrew R Conery et al. eLife
- Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways
- (2015) Jianbin Zhang et al. Autophagy
- Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
- (2015) S. Picaud et al. CANCER RESEARCH
- Autophagy signal transduction by ATG proteins: from hierarchies to networks
- (2015) Sebastian Wesselborg et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Role of Histone Acetylation in Cell Cycle Regulation
- (2015) Miglena Koprinarova et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Epigenetic regulation in human melanoma: past and future
- (2015) Debina Sarkar et al. Epigenetics
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas
- (2015) Beata Holkova et al. LEUKEMIA & LYMPHOMA
- Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma
- (2015) D. Soodgupta et al. MOLECULAR CANCER THERAPEUTICS
- Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
- (2015) Madhusoodanan Mottamal et al. MOLECULES
- Protein neddylation: beyond cullin–RING ligases
- (2015) Radoslav I. Enchev et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Interplay between unfolded protein response and autophagy promotes tumor drug resistance
- (2015) MING-MING YAN et al. Oncology Letters
- Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
- (2015) Gabor Borbely et al. Oncotarget
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial
- (2015) Daryl Tan et al. Lancet Haematology
- Hsp90, the Concertmaster: Tuning Transcription
- (2015) Nidhi Khurana et al. Frontiers in Oncology
- A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer
- (2015) Ya-Ting Yang et al. NEOPLASIA
- Activation of the Unfolded Protein Response Contributes toward the Antitumor Activity of Vorinostat
- (2015) Soumen Kahali et al. NEOPLASIA
- Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration
- (2014) Victoria Zismanov et al. ANTI-CANCER DRUGS
- Combined autophagy and HDAC inhibition
- (2014) Devalingam Mahalingam et al. Autophagy
- MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells
- (2014) Y. Gu et al. BLOOD
- Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
- (2014) Jean-Pierre Issa et al. CANCER
- The ubiquitin–proteasome system: opportunities for therapeutic intervention in solid tumors
- (2014) Daniel E Johnson ENDOCRINE-RELATED CANCER
- Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
- (2014) Sridurga Mithraprabhu et al. Epigenetics
- Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids
- (2014) Kunal Nepali et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate
- (2014) Sabita N. Saldanha et al. EXPERIMENTAL CELL RESEARCH
- HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes
- (2014) Monika Noack et al. GLIA
- The BET Bromodomain Inhibitor I-BET151 Acts Downstream of Smoothened Protein to Abrogate the Growth of Hedgehog Protein-driven Cancers
- (2014) Jun Long et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of HDAC6 Modifies Tau Inclusion Body Formation and Impairs Autophagic Clearance
- (2014) Janina Leyk et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
- (2014) Duncan A. Hay et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
- (2014) A Moros et al. LEUKEMIA
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes
- (2014) Stephen J. Atkinson et al. MedChemComm
- Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
- (2014) E. Seto et al. Cold Spring Harbor Perspectives in Biology
- Molecular Chaperones, Cochaperones, and Ubiquitination/Deubiquitination System: Involvement in the Production of High Quality Spermatozoa
- (2014) Rosaria Meccariello et al. Biomed Research International
- Regulation of molecular chaperones through post-translational modifications: Decrypting the chaperone code
- (2013) Philippe Cloutier et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
- (2013) A. Chaidos et al. BLOOD
- A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies
- (2013) Wei-Jan Huang et al. CANCER LETTERS
- A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors
- (2013) M New et al. CELL DEATH AND DIFFERENTIATION
- The machinery of macroautophagy
- (2013) Yuchen Feng et al. CELL RESEARCH
- Chaperone-mediated autophagy: roles in disease and aging
- (2013) Ana Maria Cuervo et al. CELL RESEARCH
- Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
- (2013) Z. Cheng et al. CLINICAL CANCER RESEARCH
- Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials
- (2013) Tianzhu Qiu et al. Future Oncology
- Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
- (2013) Tien Hoang et al. INVESTIGATIONAL NEW DRUGS
- Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
- (2013) Jesús F. San-Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
- (2013) Li Dong et al. Journal of Hematology & Oncology
- Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
- (2013) Meletios Dimopoulos et al. LANCET ONCOLOGY
- Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy
- (2013) M V Stankov et al. LEUKEMIA
- Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
- (2013) U Platzbecker et al. LEUKEMIA
- A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study
- (2013) Mark H. Kirschbaum et al. LEUKEMIA & LYMPHOMA
- Evading apoptosis in cancer
- (2013) Kaleigh Fernald et al. TRENDS IN CELL BIOLOGY
- Autophagy in tumor suppression and cancer therapy
- (2012) Che-Pei Kung et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
- (2012) Akira Fukutomi et al. INVESTIGATIONAL NEW DRUGS
- Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
- (2012) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer
- (2012) David R. Jones et al. Journal of Thoracic Oncology
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells
- (2012) Guang Yan et al. MOLECULAR CARCINOGENESIS
- HDAC inhibitor-based therapies: Can we interpret the code?
- (2012) Maria New et al. Molecular Oncology
- Epigenetic protein families: a new frontier for drug discovery
- (2012) Cheryl H. Arrowsmith et al. NATURE REVIEWS DRUG DISCOVERY
- Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells
- (2012) I. Venza et al. Pigment Cell & Melanoma Research
- Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
- (2012) W. W. Lockwood et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Cell Metabolism: One Hallmark, Many Faces
- (2012) Jason R. Cantor et al. Cancer Discovery
- Autophagy as a target for cancer therapy: new developments
- (2012) Steffan Nawrocki et al. Cancer Management and Research
- Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
- (2011) Amanda Cashen et al. ANNALS OF HEMATOLOGY
- Microautophagy: lesser-known self-eating
- (2011) Wen-wen Li et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Epigenetic Modifications
- (2011) Diane E. Handy et al. CIRCULATION
- Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
- (2011) R. K. Amaravadi et al. CLINICAL CANCER RESEARCH
- Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- Protein Aggregates Are Recruited to Aggresome by Histone Deacetylase 6 via Unanchored Ubiquitin C Termini
- (2011) Hui Ouyang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
- (2011) Anas Younes et al. LANCET ONCOLOGY
- A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517
- (2011) Mark H. Kirschbaum et al. LEUKEMIA & LYMPHOMA
- Autophagy as a target for anticancer therapy
- (2011) Filip Janku et al. Nature Reviews Clinical Oncology
- Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
- (2011) B. B. Friday et al. NEURO-ONCOLOGY
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Autophagy and apoptosis: what is the connection?
- (2011) Jacob M. Gump et al. TRENDS IN CELL BIOLOGY
- Cellular Strategies of Protein Quality Control
- (2011) B. Chen et al. Cold Spring Harbor Perspectives in Biology
- The acetylation of tau inhibits its function and promotes pathological tau aggregation
- (2011) Todd J. Cohen et al. Nature Communications
- Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma
- (2010) Yuan-Ling Liu et al. Autophagy
- The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism
- (2010) Daniela Buglio et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
- (2010) Ruben Niesvizky et al. CANCER
- The Role of HDAC6 in Cancer
- (2010) Grace I. Aldana-Masangkay et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Autophagy: cellular and molecular mechanisms
- (2010) Danielle Glick et al. JOURNAL OF PATHOLOGY
- Heat Shock Protein 90 Inhibition in Lung Cancer
- (2010) Takeshi Shimamura et al. Journal of Thoracic Oncology
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
- (2010) Eric Sanchez et al. LEUKEMIA RESEARCH
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
- (2010) O. Khan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Augmentation of the anticancer effects of proteasome inhibitors by combination with sodium butyrate in human colorectal cancer cells
- (2010) M.S.I. ABAZA Experimental and Therapeutic Medicine
- Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis
- (2009) Susan Fotheringham et al. CANCER CELL
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- Vorinostat enhances the antimyeloma effects of melphalan and bortezomib
- (2009) Richard A. Campbell et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- An operational definition of epigenetics
- (2009) S. L. Berger et al. GENES & DEVELOPMENT
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
- (2009) E. M. Ocio et al. HAEMATOLOGICA
- Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation
- (2009) Jennifer S. Carew et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Targeting proteins for degradation
- (2009) Erin K Schrader et al. Nature Chemical Biology
- Converging concepts of protein folding in vitro and in vivo
- (2009) F Ulrich Hartl et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
- (2009) C. Choudhary et al. SCIENCE
- The Effect of Proteasome Inhibition on p53 Degradation and Proliferation in Tonsil Epithelial Cells
- (2008) George F. Harris et al. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
- HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2
- (2008) Annamaria Scognamiglio et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
- (2008) W Weichert et al. BRITISH JOURNAL OF CANCER
- Role of Acetylation and Extracellular Location of Heat Shock Protein 90 in Tumor Cell Invasion
- (2008) Y. Yang et al. CANCER RESEARCH
- Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo
- (2008) W. Weichert et al. CLINICAL CANCER RESEARCH
- A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors
- (2008) N. L. Steele et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
- (2008) L. Ellis et al. CLINICAL CANCER RESEARCH
- Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers
- (2008) F. Braiteh et al. CLINICAL CANCER RESEARCH
- Heat Shock Protein 90 as a Drug Target: Some Like It Hot
- (2008) U. Banerji CLINICAL CANCER RESEARCH
- Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
- (2008) Sharmila Patel et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
- (2008) L Marquard et al. HISTOPATHOLOGY
- Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma
- (2008) S. Vincent Rajkumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
- (2008) Wilko Weichert et al. LANCET ONCOLOGY
- Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
- (2008) Paul Richardson et al. LEUKEMIA & LYMPHOMA
- Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells
- (2008) Marielle Dejligbjerg et al. Molecular Cancer
- Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells
- (2008) V. Duong et al. MOLECULAR CANCER RESEARCH
- Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
- (2008) A. Miyanaga et al. MOLECULAR CANCER THERAPEUTICS
- MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
- (2008) M. Fournel et al. MOLECULAR CANCER THERAPEUTICS
- Diversity of degradation signals in the ubiquitin–proteasome system
- (2008) Tommer Ravid et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search